Book a Meeting

BetterBet™ Anti-CD19 Half-Life Extended Antibody (CAT#: AES-0622-ZP1032) Datasheet

Target
CD19
Description
Creative Biolabs enhances the binding ability of the anti-CD19 antibody to FcRn by modifying the Fc of the antibody, thereby increasing the half-life of the anti- antibody.
Applications
Increase the half-life of antibodies
Technology
Fc engineering technology

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD19 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD19 molecule
Background
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4
Description
Creative Biolabs enhances the binding ability of the anti-CD19 antibody to FcRn by modifying the Fc of the antibody, thereby increasing the half-life of the anti- antibody.

The Fc of the antibody is engineered to enhance the binding ability of the antibody to FcRn, thereby increasing the half-life of the antibody

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany